Bedrijfsoverzicht
Pharvaris N.V. operates as a late-stage biopharmaceutical entity dedicated to the research, development, and commercialization of novel therapies designed to address rare diseases characterized by unmet medical needs, specifically within the domains of angioedema and other bradykinin-mediated conditions. The company's primary strategic focus involves the advancement of deucrictibant, which functions as a small molecule bradykinin B2-receptor antagonist intended to target specific pathological mechanisms. This enterprise functions within the broader Healthcare sector, specifically the specialized sub-industry of Biotechnology, a classification that signifies high R&D intensity and a reliance on successful product launches to generate future profitability. With a market capitalization of $1.74B and a workforce comprising 129 employees, the company occupies a niche position in the biotechnology landscape. The valuation metrics indicate that the market assigns significant worth to the company's intellectual property and pipeline potential, even though current annual revenue figures are not publicly disclosed in the provided data, suggesting that the company's valuation is heavily predicated on its developmental stage rather than established sales streams.
Financiële gezondheid
The financial performance indicators for Pharvaris N.V. reveal a company currently operating at a loss, with a reported net income of $-175,699,392 and an EBITDA of $-169,633,776 over the trailing twelve-month period. The absence of reported revenue in the available data, coupled with the substantial negative net income, highlights a cost structure dominated by research, development, and operational expenditures that exceed all current income streams. The company generated a free cash flow of $-79,089,728, indicating a significant cash outflow that reflects the capital-intensive nature of its late-stage development activities and limits immediate financial flexibility for expansion without external financing. All three key profitability margins—gross margin, operating margin, and profit margin—are reported at 0.0%, which is typical for biotechnology firms in the pre-revenue or early commercialization phase where costs are incurred before sales realization. Despite the negative earnings, the company maintains a cash balance of $291.68M against a debt obligation of $776,798, resulting in a debt-to-equity ratio of 0.29. This balance sheet structure suggests a relatively conservative leverage profile, as the company's liquid assets significantly exceed its total liabilities. The current ratio stands at 10.11, a figure that implies robust short-term liquidity and a strong ability to meet obligations due within one year without distress. Furthermore, the return on equity is -65.2% and the return on assets is -35.8%, metrics that reflect the dilutive effect of losses on shareholder equity and asset base, indicating that management is currently deploying capital to fund growth initiatives rather than generating immediate financial returns.
Waarderingsbeoordeling
Valuation multiples for Pharvaris N.V. present a complex picture due to the lack of traditional earnings generation. The trailing twelve-month P/E ratio is listed as N/A, while the forward P/E is reported at -8.47, a negative figure that mathematically implies expected future earnings are still projected to be negative, consistent with the current financial trajectory. The price-to-book ratio is 4.79, suggesting that the market values the company at a significant premium over its net asset value, a common phenomenon for biotech firms where intangible assets like patent portfolios and clinical data are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio are also N/A, and the EV/EBITDA stands at -8.55, further confirming that traditional earnings-based valuation models are not yet applicable to this asset. In terms of trading range, the stock has fluctuated between a 52-week low of $12.01 and a 52-week high of $29.85, with the current market price situated within this historical volatility band. The beta value is recorded as -2.58, a highly unusual negative coefficient that technically indicates the stock price moves inversely to the broader market, although in practice for such a company, this metric often reflects extreme idiosyncratic volatility rather than standard market correlation.
Growth & Income
Growth metrics for Pharvaris N.V. are currently characterized by the absence of historical sales data, resulting in a revenue growth year-over-year figure of N/A and an earnings growth year-over-year figure of N/A. Since neither revenue nor earnings are positive, a direct comparison of growth rates between the two is not mathematically feasible, but the negative earnings growth relative to zero revenue underscores the company's focus on spending to reach commercial milestones rather than scaling current sales. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which aligns with the strategy of retaining all available cash to fund ongoing drug development and operational costs. Consequently, the company reinvests its limited earnings and cash reserves entirely into its growth pipeline rather than distributing income to shareholders. The overall growth and income profile is defined by a complete reliance on future commercial success to transition from a cash-burning entity to a revenue-generating one, with no current income yield available to investors.